Innovative Therapeutics in Oncology and Neuroscience
POC stage
ZL-1102 (IL-17 HumabodyⓇ)
Expected to Move into Full Global Development
ZL-1102 HumabodyⓇ
13.2 kDa
High-Affinity Human VH Fragment Targeting IL-17A
First-ever study to demonstrate penetration of protein biologic through
psoriatic skin resulting in clinical response
IgG Antibody
150 kDa
Significant Global Opportunity
2
Psoriasis affects 125 million 3 people
worldwide
80-90% 3,4 suffer from plaque psoriasis;
70-80% 5 of these cases are mild-to-
moderate
⚫ Most systemic agents including recent
orals and injectables are prescribed for
moderate-to-severe psoriasis only
- ZL-1102 BID (N-26) +- Vehicle BID (N=25)
45% relative
-10-
improvement
-20-
-30-
-40-
Baseline
D8
D15
D22
D29
D43
visit
Consistent improvement in
responder rates¹ over time
35%
31%
30%
27%
25%
23%
19%
20%
20%
16%
15%
10%
8%
4%
12%
4%
5%
0%
Week 1
(Day 8)
Week 2 Week 3 Week 4
(Day 15) (Day 22) (Day 29)
Week 6
(Day 43)
■ZL-1102 BID Vehicle BID
Local PASI score: 45% relative improvement at Day 29
Safety/tolerability profile indistinguishable from placebo
Transcriptome analysis shows clear differential effect with topical ZL-1102
•
Downregulated genes enriched in immune response pathway
•
Decrease in K16 marker expression²
Zai Lab to initiate the global Phase 2 study for dose selection and safety / efficacy with prolonged treatment in mid-24
41
Abbreviation: Psoriasis Area Severity Index (PASI).
Notes: Humabody is a registered trademark of Crescendo Biologics. (1) Responder rate: % patients who achieved a ≥50% reduction in local PASI score of target lesion; (2) K16 marker indicative of downregulated cell proliferation; (3) National Psoriasis
Foundation. The impact of psoriasis. https://www.psoriasis.org/psoriasis-statistics/; (4) Menter A. J Am Acad Dermatol. 2008; 58:826-50.; (5) K Papp.. Dermatol Ther 11: 1053; 2021.
Clinical Data -
AutoimmuneView entire presentation